Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 19 % of short-term debt in 2025; threshold 65 %.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2025
GenomiX from Liège, company number BE0757949684, closed financial year 2025 with a result of € 9,134 after tax. For that financial year GenomiX recorded a gross margin of € -1,109 and equity of € 255,524. Compared with financial year 2024, the result moved from € 9,135 to € 9,134. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.
€ 255,524
▲ 4% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 9,134
Profit after tax over the fiscal year.
€ 5,798
▲ 37% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 30,524.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 1,109
▼ 19% vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | - | € -812 | € -1,314 | € -1,109 | ▲ € 205 |
| Profit after taxes | € 13,027 | € 9,316 | € 9,135 | € 9,134 | |
| Equity | € 227,939 | € 237,255 | € 246,391 | € 255,524 | ▲ 4% |
| Total debts | € 85,166 | € 88,034 | € 85,904 | € 88,350 | ▲ 3% |
| Cash | € 5,028 | € 7,212 | € 4,218 | € 5,798 | ▲ 37% |
| Retained profit | € 2,939 | € 12,255 | € 21,391 | € 30,524 | ▲ 43% |
| Balance sheet total | € 313,105 | € 325,289 | € 332,295 | € 343,875 | ▲ 3% |
Key figures of GenomiX, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to GenomiX?
What happened at GenomiX in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 9,134. filed late Source: NBB ↗
- Benoît GLAUDE became a director. NBB
- New establishment in Liège. KBO
- Christophe GREFFE became a director. NBB
- Nicolas POELST became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 13,027 profit in 2022 to € 9,134 profit in 2025.
Best year ever: 2022, with € 13,027 profit.
A new publication or filing at GenomiX? We notify you, reason included.
Follow GenomiXDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind GenomiX are Christophe GREFFE, Benoît GLAUDE and Nicolas POELST. It owns 62% of REPROBIOL itself.
Establishments
Establishment units
Physical locations of this company
Allée de la Cense-Rouge 9
4031 Liège
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0757.949.684
- VAT number
- BE 0757.949.684
- Registered office
- Allée de la Cense-Rouge 9, 4031 Liège
- Names & denominations
- GenomiX
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 10 November 2020
- Peppol
- Not registered
- Contact
- [email protected]